Gene therapy for cystic fibrosis

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 4, 1999, Pages 510-516

  Flotte, Terence R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS VECTOR;

ADENOVIRUS; CYSTIC FIBROSIS; DRUG RESEARCH; EQUINE INFECTIOUS ANEMIA VIRUS; GENE TARGETING; GENE THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MURINE LEUKEMIA VIRUS; NONHUMAN; PATHOPHYSIOLOGY; RESPIRATORY EPITHELIUM; REVIEW; TREATMENT OUTCOME;

ADENOVIRIDAE; AIRWAY OBSTRUCTION; ANIMALS; CLINICAL TRIALS, PHASE I; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DEFECTIVE VIRUSES; DEPENDOVIRUS; DNA, RECOMBINANT; GENE THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; LIPOSOMES; LUNG; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; VEHICLES;

ADENOVIRIDAE; EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MURINAE; MURINE LEUKEMIA VIRUS;

EID: 0032883105     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, Paakko PK, Gilardi P, Stratford-Perricaudet LD, Perricaudet M, et al: Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science (1991) 252(5004):431-434.
2. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford-Perricaudet L, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell (1992) 68(1):143-155.
3. Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R, Oka H, Zeitlin PL, Guggino WB, Carter BJ: Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA (1993) 90(22):10613-10617.
4. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT, Danel C: Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet (1994) 8(1):42-51.
5. Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, Taylor G, Walden S, Wetzel R: A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther (1996) 7(9):1145-1159.
6. Stern M, Caplen NJ, Browning JE, Griesenbach U, Sorgi F, Huang L, Gruenert DC, Marriot C, Crystal RG, Geddes DM, Alton EW: The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther (1998) 5(1):91-98.
7. van Heeckeren A, Ferkol T, Tosi M: Effects of bronchopulmonary inflammation induced by pseudomonas aeruginosa on adenovirus-mediated gene transfer to airway epithelial cells in mice. Gene Ther (1998) 5(3):345-351.
8. Davis PB, Drumm M, Konstan MW: Cystic fibrosis. Am J Respir Crit Care Med (1996) 154(5):1229-1256.
9. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM: Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell (1997) 88(4):553-560.
10. Bals R, Goldman MJ, Wilson JM: Mouse beta-defensin 1 is a salt-sensitive antimicrobial peptide present in epithelia of the lung and urogenital tract. Infect Immun (1998) 66(3):1225-1232.
11. Daher KA, Selsted ME, Lehrer RI: Direct inactivation of viruses by human granulocyte defensins. J Virol (1986) 60(3):1068-1074.
12. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI: Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest (1985) 76(4):1427-1435.
13. LeVine AM, Kurak KE, Bruno MD, Stark JM, Whitsett JA, Korfhagen TR: Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol (1998) 19(4):700-708.
14. LeVine AM, Gwozdz J, Stark J, Bruno M, Whitsett J, Korfhagen T: Surfactant protein-A enhances respiratory syncytial virus clearance in vivo. J Clin Invest (1999) 103(7):1015-1021.
15. LeVine AM, Bruno MD, Huelsman KM, Ross GF, Whitsett JA, Korfhagen TR: Surfactant protein A-deficient mice are susceptible to group B streptococcal infection. J Immunol (1997) 158(9):4336-4340
16. Black HR, Yankaskas JR, Johnson LG, Noah TL: Interleukin-8 production by cystic fibrosis nasal epithelial cells after tumor necrosis factor-alpha and respiratory syncytial virus stimulation. Am J Respir Cell Mol Biol (1998) 19(2):210-215.
17. DiMango E, Ratner AJ, Bryan R, Tabibi S, Prince A: Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest (1998) 101(11):2598-2605.
18. Dosanjh AK, Elashoff D, Robbins RC: The bronchoalveolar lavage fluid of cystic fibrosis lung transplant recipients demonstrates increased interleukin-8 and elastase and decreased IL-10. J Interferon Cytokine Res (1998) 18(10):851-854.
19. Van Wetering S, Mannesse-Lazeroms SP, Dijkman JH, Hiemstra PS: Effect of neutrophil serine proteinases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production. J Leukocyte Biol (1997) 62(2):217-226.
20. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (1989) 245(4922):1066-1073.
21. Welsh MJ, Smith AE: Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell (1993) 73(7):1251-1254.
22. Anderson MP, Rich DP, Gregory RJ, Smith AE, Welsh MJ: Generation of cAMP-activated chloride currents by expression of CFTR. Science (1991) 251(4994):679-682.
23. Rich DP, Anderson MP, Gregory RJ, Cheng SH, Paul S, Jefferson DM, McCann JD, Klinger KW, Smith AE, Welsh MJ: Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature (1990) 347(6291):358-363.
24. Berger HA, Anderson MP, Gregory RJ, Thompson S, Howard PW, Maurer RA, Mulligan R, Smith AE, Welsh MJ: Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel. J Clin Invest (1991) 88(4):1422-1431.
25. Schultz BD, Venglarik CJ, Bridges RJ, Frizzell RA: Regulation of CFTR Cl channel gating by ADP and ATP analogues. J Gen Physiol (1995) 105(3):329-361.
26. Engelhardt JF, Yankaskas JR, Ernst SA, Yang Y, Marino CR, Boucher RC, Cohn JA, Wilson JM: Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nature Genet (1992) 2(3):240-248.
27. Sehgal A, Presente A, Engelhardt JF: Developmental expression patterns of CFTR in ferret tracheal surface airway and submucosal gland epithelia. Am J Respir Cell Mol Biol (1996) 15(1):122-131.
28. Egan M, Flotte T, Afione S, Solow R, Zeitlin PL, Carter BJ, Guggino WB: Defective regulation of outwardly rectifying CI channels by protein kinase A corrected by insertion of CFTR. Nature (1992) 358(6387):581-584.
29. Schwiebert EM, Egan ME, Hwang TH, Fulmer SB, Allen SS, Cutting GR, Guggino WB: CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell (1995) 81(7):1063-1073.
30. Stutts MJ, Rossier BC, Boucher RC: Cystic fibrosis transmembrane conductance regulator inverts protein kinase A-mediated regulation of epithelial sodium channel single channel kinetics. J Biol Chem (1997) 272(22): 14037-14040.
31. Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T: Excessive Inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest (1997) 100(11):2810-2815.
32. Smith JJ, Travis SM, Greenberg EP, Welsh MJ: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell (1996) 85(2):229-236.
33. Crystal RG, Jaffe A, Brody S, Mastrangeli A, McElvaney NG, Rosenfeld M, Chu CS, Danel C, Hay J, Eissa T: A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung. Hum Gene Ther (1995) 6(5):643-666.
34. Knowles MR. Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu PC, Leigh MW, Engelhardt JF, Edwards LJ, Jones KR, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med (1995) 333(13):823-831.
35. Boucher RC, Knowles MR, Johnson LG, Olsen JC, Pickles R, Wilson JM, Engelhardt J, Yang Y, Grossman M: Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill. Hum Gene Ther (1994) 5(5):615-639.
36. Simon RH, Engelhardt JF, Yang Y, Zepeda M, Weber-Pendleton S, Grossman M, Wilson JM: Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. Hum Gene Ther (1993) 4(6):771-780.
37. Wilmott RW, Amin RS, Perez CR, Wert SE, Keller G, Boivin GP, Hirsch R, De Inocencio J, Lu P, Reising SF, Yei S, Whitsett JA, Trapnell BC: Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates. Hum Gene Ther (1996) 7(3):301-318.
38. Afione SA, Conrad CK, Kearns WG, Chunduru S, Adams R, Reynolds TC, Guggino WB, Cutting GR, Carter BJ, Flotte TR: In vivo model of adeno-associated virus vector persistence and rescue. J Virol (1996) 70(5):3235-3241.
39. Otake K, Ennist DL, Harrod K, Trapnell BC: Nonspecific Inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum Gene Ther (1998) 9(15):2207-2222.
40. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM: Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther (1996) 3(2):137-144.
41. Yang Y, Su Q, Wilson JM: Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol (1996) 70(10):7209-7212.
42. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA (1994) 91(10):4407-4411.
43. Yang Y, Ertl HC, Wilson JM: MHC class l-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity (1994) 1(5):433-442.
44. Yei S, Mittereder N, Tang K, O'Sullivan C, Trapnell BC: Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther (1994) 1(3):192-200.
45. Yang Y, Nunes FA, Berencsi K, Gönczöl E, Engelhardt JF, Wilson JM: Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet (1994) 7(3):362-369.
46. Gao GP, Yang Y, Wilson JM: Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol (1996) 70(12):8934-8943.
47. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM: Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology (1996) 217(1):11-22.
48. Yang Y, Greenough K, Wilson JM: Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther (1996) 3(5):412-420.
49. Yang Y, Su Q, Grewal IS, Schilz R, Flavell RA, Wilson JM: Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol (1996) 70(9):6370-6377.
50. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M, Berns KI: Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA (1990) 87(6):2211-2215.
51. Kotin RM, Menninger JC, Ward DC, Berns KI: Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics (1991) 10(3):831-834.
52. Kotin RM, Linden RM, Berns KI: Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J (1992) 11(13):5071-5078.
53. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA: Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J (1991) 10(12):3941-3950.
54. Weitzman MD, Kyöstiö SR, Kotin RM, Owens RA: Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA (1994) 91(13):5808-5812.
55. Tratschin JD, West MH, Sandbank T, Carter BJ: A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol (1984) 4(10):2072-2081.
56. Hermonat PL, Muzyczka N: Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA (1984) 81(20):6466-6470.
57. Flotte TR, Afione SA, Zeitlin PL: Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol (1994) 11(5):517-521.
58. Kearns WG, Afione SA, Fulmer SB, Pang MC, Erikson D, Egan M, Landrum MJ, Flotte TR, Cutting GR: Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther (1996) 3(9):748-755.
59. Flotte TR, Solow R, Owens RA, Afione S, Zeitlin PL, Carter BJ: Gene expression from adeno-associated virus vectors in airway epithelial cells. Am J Respir Cell Mol Biol (1992) 7(3):349-356.
60. Flotte TR, Afione SA, Solow R, Drumm ML, Markakis D, Guggino WB, Zeitlin PL, Carter BJ: Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem (1993) 268(5):3781-3790.
61. Baudard M, Flotte TR, Aran JM, Thierry AR, Pastan I, Pang MG, Kearns WG, Gottesman MM: Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes. Hum Gene Ther (1996) 7(11):1309-1322.
62. Schwiebert EM, Flotte T, Cutting GR, Guggino WB: Both CFTR and outwardly rectifying chloride channels contribute to cAMP- stimulated whole cell chloride currents. Am J Physiol (1994) 266(5 Pt 1):C1464-C1477.
63. Flotte TR, Beck SE, Chesnut K, Potter M, Poirier A, Zolotukhin S: A fluorescence video-endoscopy technique for detection of gene transfer and expression. Gene Ther (1998) 5(2):166-173.
64. Conrad CK, Allen SS, Afione SA, Reynolds TC, Beck SE, Fee-Maki M, Barrazza-Ortiz X, Adams R, Askin FB, Carter BJ, Guggino WB, Flotte TR: Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther (1996) 3(8):658-668.
65. Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, Flotte TR, Gardner P: Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet (1998) 351(9117):1702-1703.
66. Wagner JA, Moran ML, Messner AH, Daifuku R, Conrad CK, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P: A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther (1998) 9(6):889-909.
67. Wagner JA, Moran ML, Daifuku R, Kouyama K, Desch JK, Manly S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P: Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane conductance regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope (1999) 109:266-274.
68. Teramoto S, Barten JS, McCarty D, Xiao X, Samulski RJ, Boucher RC: Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: comparison with adenovirus vectors. J Virol (1998) 72(11):8904-8912.
69. Duan D, Yue Y, Van Z, McCray PB Jr, Engelhardt JF: Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia. Hum Gene Ther (1998) 9(18):2761-2776.
70. Bals R, XW, Sang N, Weiner DJ, Meegalla RL, Wilson JM: Transduction of well-differentiated airway epithelium by recombinant adeno-associated virus is limited by vector entry. J Virol (1999) 73(7):6085-6088.
71. Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, Durham SR, Jeffery PK, Hodson ME, Coutelle C, et al: Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Med (1995) 1(1):39-46.
72. Zabner J, Cheng SH, Meeker D, Launspach J, Balfour R, Perricone MA, Morris JE, Marshall J, Fasbender A, Smith AE, Welsh MJ: Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J Clin Invest (1997) 100(6):1529-1537.
73. Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Davidson H, Stevenson BJ, Carothers AD, Wallace WA, Moralee S, Hoenes C, Kallmeyer G, Michaelis U, Naujoks K, Ho LP, Samways JM, Imrie M, Greening AP, Innes JA: Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther (1997) 4(3):210-218.
74. Chadwick SL, Kingston HD, Stern M, Cook RM, O'Connor BJ, Lukasson M, Balfour RP, Rosenberg M, Cheng SH, Smith AE, Meeker DP, Geddes DM, Alton EW: Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers. Gene Ther (1997) 4(9):937-942.
75. Knowles MR, Noone PG, Hohneker K, Johnson LG, Boucher RC, Elthimiou J, Crawford C, Brown R, Schwartzbach C, Pearlman R: A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. Hum Gene Ther (1998) 9(2):249-269.
76. Alton EW, Middleton PG, Caplen NJ, Smith SN, Steel DM, Munkonge FM, Jeffrey PK, Geddes DM, Hart SL, Williamson R: Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice [published erratum appears in Nature Genet 1993 5(3):312]. Nature Genet (1993) 5(2):135-142.
77. Ferkol T, Kaetzel CS, Davis PB: Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor. J Clin Invest (1993) 92(5):2394-2400.
78. Ferkol T, Perales JC, Eckman E, Kaetzel CS, Hanson RW, Davis PB: Gene transfer into the airway epithelium of animals by targeting the polymeric immunoglobulin receptor. J Clin Invest (1995) 95(2):493-502.
79. Perales JC, Ferkol T, Molas M, Hanson RW: An evaluation of receptor-mediated gene transfer using synthetic DNA-ligand complexes. Eur J Biochem (1994) 226(2):255-266.
80. Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW: Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci USA (1994) 91(9):4086-4090.
81. Ferkol T, Pellicena-Palle A, Eckman E, Perales JC, Trzaska T, Tosi M, Redline R, Davis PB: Immunologic responses to gene transfer into mice via the polymeric immunoglobulin receptor. Gene Ther (1996) 3(8):669-678.
82. Culver KW, Morgan RA, Osborne WR, Lee RT, Lenschow D, Able C, Cornetta K, Anderson WF, Baese RM: In vivo expression and survival of gene-modified T lymphocytes in rhesus monkeys. Hum Gene Ther (1990) 1(4):399-410.
83. McCray PB Jr: In-utero gene transfer - an approach to the treatment of inherited lung diseases. Mol Hum Reprod (1996) 2(7):469-471.
84. Goldman MJ, Lee PS, Yang JS, Wilson JM: Lentiviral vectors for gene therapy of cystic fibrosis. Hum Gene Ther (1997) 8(18):2261-2268.
85. Poeschla EM, Wong-Staal F, Looney DJ: Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nature Med (1998) 4(3):354-357.
86. Olsen JC: Gene transfer vectors derived from equine infectious anemia virus. Gene Ther (1998) 5(11):1481-1487.